Zymeworks Inc. Common Stock

Company Profile

Zymeworks Inc. Common Stock had its IPO on 2017-04-28 under the ticker symbol ZYME.

The company operates in the Healthcare sector and Biotechnology industry. Zymeworks Inc. Common Stock has a staff strength of 304 employees.

Stock update

Shares of Zymeworks Inc. Common Stock opened at $8.5 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $8.38 - $8.68, and closed at $8.67.

This is a +2.12% increase from the previous day's closing price.

A total volume of 210,784 shares were traded at the close of the day’s session.

In the last one week, shares of Zymeworks Inc. Common Stock have slipped by -1.48%.

Zymeworks Inc. Common Stock's Key Ratios

Zymeworks Inc. Common Stock has a market cap of $556.37 million, indicating a price to book ratio of 1.7819 and a price to sales ratio of 13.3063.

In the last 12-months Zymeworks Inc. Common Stock’s revenue was $446.14 million with a gross profit of $203.78 million and an EBITDA of $180.72 million. The EBITDA ratio measures Zymeworks Inc. Common Stock's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zymeworks Inc. Common Stock’s operating margin was 39.16% while its return on assets stood at 21.19% with a return of equity of 45.67%.

In Q1, Zymeworks Inc. Common Stock’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1756.9%.

Zymeworks Inc. Common Stock’s PE and PEG Ratio

Forward PE

0

Trailing PE

3.0104

PEG

0

Its diluted EPS in the last 12-months stands at $2.88 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zymeworks Inc. Common Stock’s profitability.

Zymeworks Inc. Common Stock stock is trading at a EV to sales ratio of 5.8898 and a EV to EBITDA ratio of -0.8146. Its price to sales ratio in the trailing 12-months stood at 13.3063.

Zymeworks Inc. Common Stock stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$600.74 million

Total Liabilities

$67.32 million

Operating Cash Flow

$0

Capital Expenditure

$386000

Dividend Payout Ratio

0%

Zymeworks Inc. Common Stock ended 2023 with $600.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $600.74 million while shareholder equity stood at $-583116000.00.

Zymeworks Inc. Common Stock ended 2023 with $0 in deferred long-term liabilities, $67.32 million in other current liabilities, 909916000.00 in common stock, $-583116000.00 in retained earnings and $12.02 million in goodwill. Its cash balance stood at $181.58 million and cash and short-term investments were $412.38 million. The company’s total short-term debt was $3,372,000 while long-term debt stood at $0.

Zymeworks Inc. Common Stock’s total current assets stands at $426.37 million while long-term investments were $72.47 million and short-term investments were $159.21 million. Its net receivables were $66.92 million compared to accounts payable of $6.43 million and inventory worth $0.

In 2023, Zymeworks Inc. Common Stock's operating cash flow was $0 while its capital expenditure stood at $386000.

Comparatively, Zymeworks Inc. Common Stock paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$8.67

52-Week High

$10.8

52-Week Low

$4.11

Analyst Target Price

$14

Zymeworks Inc. Common Stock stock is currently trading at $8.67 per share. It touched a 52-week high of $10.8 and a 52-week low of $10.8. Analysts tracking the stock have a 12-month average target price of $14.

Its 50-day moving average was $9.08 and 200-day moving average was $7.83 The short ratio stood at 11.73 indicating a short percent outstanding of 0%.

Around 499.1% of the company’s stock are held by insiders while 10111.7% are held by institutions.